ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1552

No Effect of Concomitant Glucocorticoid Therapy on Efficacy and Safety of Tocilizumab Monotherapy Found in Rheumatoid Arthritis Clinical Trials

Mary Safy1, Johannes W. G. Jacobs1, Michael Edwardes2, Maria JH de Hair1, Xavier M Teitsma1, Paco MJ Welsing1, Michelle EA Borm3, Yves Luder4, Jacob van Laar1, Attila Pethö-Schramm4 and Johannes W. J. Bijlsma5, 1Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands, 2Everest Clinical Research, Markham, ON, Canada, 3Roche Nederland BV, Woerden, Netherlands, 4F. Hoffmann-La Roche, Basel, Switzerland, 5Rheumatology & Clinical Immunology department University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Biologic agents, clinical trials, Effective, rheumatoid arthritis (RA) and safety

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

No effect of concomitant glucocorticoid therapy on efficacy and safety of tocilizumab monotherapy in rheumatoid arthritis clinical trials

M. Safy1, J.W.G. Jacobs1, M. Edwardes2, M.J.H. de Hair1, X.M. Teitsma1, P.M.J. Welsing1, M.E.A. Borm3, Y. Luder4, J.M. van Laar1, A. Pethö-Schramm4, J.W.J. Bijlsma1

1 Dept. of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands, 2 Everest Clinical Research, Canada, 3 Roche Nederland BV, Woerden, the Netherlands, 4 F Hoffmann-La Roche, Basel, Switzerland

 

 

Background/Purpose: Among RA patients in clinical trials, background treatment with glucocorticoids (GCs) is common. The potential impact of GCs on safety of the DMARD tested in these trials has rarely been evaluated. Our aims were to establish whether a stable concomitant GC treatment influenced: 1) efficacy and safety of tocilizumab (TCZ) monotherapy initiated in RA patients in TCZ RCTs and 2) efficacy and safety in the comparator arms of these trials, in which adalimumab (ADA) or methotrexate (MTX) was initiated.

Methods: Data were used from 4 RCTs including AMBITION, ACT-RAY, ADACTA and FUNCTION with TCZ monotherapy arms. Patients had discontinued bDMARDs or were bDMARD naïve and MTX-naïve, MTX-intolerant or MTX inadequate responders. Stable GC dose at baseline was allowed. Differences in change from baseline up to week 24 in CDAI and DAS28 between GC-users and non-GC-users were analysed using ANCOVA. Difference in radiographic progression up to week 104 between GC-users and non-GC-users was analysed. Incidence rates of SAEs were assessed by GC use.

Results: Baseline characteristics were  comparable between GC users and non-GC users within RCTs. No significant differences were found in DAS28 change or CDAI change from baseline to 24 weeks, nor in CDAI remission percentages and ACR50 response at 24 weeks, between GC users and non-GC users in TCZ, ADA, or MTX arms (Figure). In the MTX arm a significant difference in radiographic progression was found, in favour of GC use. SAE rates were numerically higher for GC users vs non-GC users in MTX and ADA arms (Table), however this difference was not tested statistically.

Conclusion: In 4 RA TCZ clinical trials, no effect of stable concomitant GC treatment at baseline and continued during the trial was found on efficacy of MTX or TCZ or ADA monotherapy. The SAE rate was numerically higher in GC users compared to non-GC users in the MTX and ADA monotherapy arms.  

 

 

 

 

 

 

 

 

 

 

 

 

 

 


Disclosure: M. Safy, AstraZeneca, 2; J. W. G. Jacobs, None; M. Edwardes, Everest Clinical Research, 3; M. J. de Hair, None; X. M. Teitsma, None; P. M. Welsing, None; M. E. Borm, Roche, 3; Y. Luder, F. Hoffmann-La Roche, 1,F. Hoffmann-La Roche, 3; J. van Laar, Roche, 5,Genentech, Inc., 2; A. Pethö-Schramm, Roche, 3; J. W. J. Bijlsma, Roche, SUN, 5.

To cite this abstract in AMA style:

Safy M, Jacobs JWG, Edwardes M, de Hair MJ, Teitsma XM, Welsing PM, Borm ME, Luder Y, van Laar J, Pethö-Schramm A, Bijlsma JWJ. No Effect of Concomitant Glucocorticoid Therapy on Efficacy and Safety of Tocilizumab Monotherapy Found in Rheumatoid Arthritis Clinical Trials [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/no-effect-of-concomitant-glucocorticoid-therapy-on-efficacy-and-safety-of-tocilizumab-monotherapy-found-in-rheumatoid-arthritis-clinical-trials/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/no-effect-of-concomitant-glucocorticoid-therapy-on-efficacy-and-safety-of-tocilizumab-monotherapy-found-in-rheumatoid-arthritis-clinical-trials/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology